Clark Wesley 4
4 · ImmunityBio, Inc. · Filed Jun 10, 2026
Research Summary
AI-generated summary of this filing
ImmunityBio Director Clark Wesley Receives 65,600-Share Award
What Happened
- Clark Wesley, a director of ImmunityBio, Inc. (IBRX), received a grant of 65,600 shares on 2026-06-09. The filing records the award as acquired at $0.00 (derivative award/compensation), so no cash was paid. The grant is recorded as an award rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-09; Filing date: 2026-06-10 (Form 4 filed within the normal two-business-day window).
- Number of shares awarded: 65,600; Reported price: $0.00 (award/compensation).
- Shares owned after transaction: Not specified in the filing.
- Vesting/conditions: Per footnote, 100% of the shares vest on the earlier of June 9, 2027 or the day immediately preceding the next annual meeting of stockholders, provided Wesley remains a Service Provider under the 2025 Equity Incentive Plan.
- Remarks: Filing includes Exhibit 24 — Power of Attorney.
- Filing timeliness: Not late (filed promptly).
Context
- This is a time‑based equity award (derivative/compensation) subject to a one-year-ish cliff vesting date; it is not an open‑market purchase or a sale. Such grants are common for director compensation and do not by themselves indicate buying or selling sentiment.
Insider Transaction Report
Form 4
Clark Wesley
Director
Transactions
- Award
Stock Option (right to buy)
[F1]2026-06-09+65,600→ 65,600 totalExercise: $7.25Exp: 2036-06-09→ Common Stock (65,600 underlying)
Footnotes (1)
- [F1]Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.
Signature
/a/ David C. Sachs, as Attorney-in-Fact|2026-06-10